Bausch Health Companies Inc. develops, manufactures and markets a wide range of branded, generic and branded generic pharmaceuticals as well as over-the-counter (OTC) products in the therapeutic ...

Shares of Bausch Health Companies Inc. BHC gained 12.6% after the company reported better-than-expected third-quarter results ...

Bausch Health Companies (NYSE:BHC – Free Report) had its price target increased by Royal Bank of Canada from $10.00 to $11.00 ...

Steve Scala, an analyst from TD Cowen, maintained the Hold rating on Bausch Health Companies (BHC – Research Report). The associated ...

Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

"Our team at Bausch Health continued to execute against our commitments in ... These results reflect the strength of our diverse and robust portfolio of products, both geographically and across ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Bausch Health shares rose Thursday morning after the company raised its full year outlook following a better-than-expected third-quarter performance. Shares traded over 11% higher in Toronto at 12.68 ...

For Bausch Health, excluding Bausch + Lomb ... Latin America and Canada, broad portfolio of products, as we reported this quarter, growing very nicely. We continue to focus to do business ...

Shares of Bausch Health Companies Inc. BHC gained 12.6% ... International, Diversified Products, Solta Medical and Bausch + Lomb. Salix revenues totaled $642 million, up 5% year over year.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Consolidated Net Loss Attributable to Bausch Health Consolidated net loss attributable to Bausch Health for the third quarter of 2024 was $85 million, compared with $378 million for the third quarter ...